Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Asthma
Dosing of first patient in trial of IV zileuton completed by Critical Therapeutics
March 24th, 2006
Critical Therapeutics, Inc., ( CRTX) announced that it has enrolled and dosed the first patient in its phase I/II clinical trial of intravenous (IV) zileuton in patients with asthma. The double-blind, placebo-controlled, single-dose trial is being conducted at multiple centers in the United States. The phase I/II clinical trial is designed to evaluate the IV formulation's safety, tolerability, pharmacokinetics, and preliminary efficacy in 60 patients, prescreened for response to oral zileuton, whose baseline lung function is 40-80% of predicted normal, as measured by FEV1 (forced expiratory volume). It is the first time an IV formulation of a...
Source: Drug Week (2006-03-24)
|
